COMPANY PROFILE

Exalys Therapeutics

Explore full profile

Developing a portfolio of novel anti-inflammatory therapeutics

San Diego, United StatesFounded 2018Biotech & Life Sciences

Valuation $50–100M Last recorded · 2020

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Exalys Therapeutics

Exalys Therapeutics is a biotechnology company focused on developing a portfolio of novel anti-inflammatory therapeutics. These therapeutics are designed to address a range of diseases that have urgent unmet needs and limited treatment options. The company's initial focus is on postoperative delirium, a common complication in older patients undergoing surgery, which significantly impacts health outcomes. Exalys Therapeutics aims to expand its product candidates to treat other acute and chronic diseases with high societal impacts. The company operates in the biopharmaceutical market, targeting healthcare providers and institutions that require advanced therapeutic solutions. Exalys generates revenue through the development and potential commercialization of its therapeutic products, leveraging its proprietary technology and expertise in pharmacology. The business model includes partnerships, licensing agreements, and direct sales to healthcare entities.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: San Diego, United States
Open positions: None listed
Dealroom signal: 21.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jul 2020	$15M	$60M	Domain Associates · Catalys Pacific	—

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Exalys Therapeutics website traffic

Latest recorded traffic for Exalys Therapeutics is 200 monthly website visits, up 66.7% over the last three months.

Latest monthly visits200 3-month web change+66.7%

Monthly website visitsAug 2020–Dec 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational	10	$616K	$2.5M
CBContraria BiotechDevelops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics	Siena, Italy	Operational
UNUnlearn Reinventing Clinical Trials	San Francisco, United States	Operational
BTBlack Diamond TherapeuticsBlack Diamond Therapeutics is a Biotechnology company	Cambridge, United States	Operational
RLReverie LabsReverie Labs (YC W18) optimizes potential medicines using machine learning	Cambridge, United States	Acquired
SOSentinel OncologyTargeted oncology candidate drugs for brain tumours	Cambridge, United Kingdom	Operational
GTGain TherapeuticsPreclinical stage biotech company developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx® technology	Lugano, Switzerland	Operational
BIBioNTechDevelops personalized immunotherapies with a focus on cancer medicine	Mainz, Germany	Operational